Experiment 1072281
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Brucea antidysenterica (SIMAROUBACEAE) |
| Citation | GARNICK,MB: BLUM,RH: CANELLOS,GP: MAYER,RJ: PARKER,L: SKARIN,AT: LI,FP: HENDERSON,IC: FREI III,E:. (1979). PHASE I TRIAL OF BRUCEANTIN.. 63() |
| Amount utilized | |
| Compound isolated | |
| Disease | PHASE I TRIAL IN 33 PATIENTS WITH ADVANCED SOLID TUMORS OR HEMATOLOGIC NEOPLASMS ANOREXIA AND NAUSEA WERE THE MOST COMMON COMPLAINTS AND LASTED 24-36 HOURS AFTER DRUG ADMINISTRATION.VOMITING LASTED 3 DAYS. HEMATOLOGIC TOXICITY(WBC,RBC,PLATELET,CLOTTING)DID NOT OCCUR IN ANY PATIENTS. ALOPECIA WAS MILD AND REVERSIBLE RENAL TOXICITY WAS NOT OBSERVED DOSE WAS FOUR TIMES WEEKLY AT ONE DOSE LEVEL FOLLOWED BY A 2 WEEK "NO TREATMENT" PERIOD:THIS PROGRAM BEING REPEATED EVERY 6 WEEKS SYSTOLIC AND DIASTOLIC HYPOTENSION WAS BOTH DOSE-RELATED AND DOSE LIMITING AT HIGHER DOSE LEVELS FEBRILE REACTIONS WERE NOTED IN 70 OF 156 DOSES (45%) GASTRO INTESTINAL TOXICITY IN 55 OF 156 DOSES(35%),BUT NO CLEAR DOSE RELATIONSHIP ONE PATIENT WITH INSULIN: REQUIRING DIABETES MELLITUS REQUIRED A DOUBLING OF THE INSULIN DOSE AFTER RECEIVING BRUCEANTIN NONE OF 18 EVALUABLE PATIENTS ACHIEVED AN OBJECTIVE 50% TUMOR REGRESSION |
| Dose amount | 5.5 MG |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |